Obesity and hypertensive heart disease: focus on body composition and sex differences by Giovanni de Simone et al.
de Simone et al. Diabetol Metab Syndr  (2016) 8:79 
DOI 10.1186/s13098-016-0193-x
REVIEW
Obesity and hypertensive heart disease: 
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Abstract 
There is evidence that hypertension is frequently associated with overweight/obesity even in kids and adolescents. 
Either conditions influence development of left ventricular (LV) hypertrophy (LVH), through different biological and 
hemodynamic mechanisms: obesity is conventionally thought to elicit a coherent growth of LV chamber dimen-
sions and myocardial wall thickness (eccentric LV geometry), whereas a more accentuated increase in wall-thickness 
(concentric LV geometry) is attributed to hypertension. While during youth these differences are visible, proportion 
of LV concentric geometry, the most harmful LV geometric pattern, sharply raises in obese individuals during middle 
age, and becomes the most frequent geometric patterns among obese-hypertensive individuals. Two conditions with 
elevated hemodynamic impact, severe obstructive sleep apnea and masked hypertension contribute to the develop-
ment of such a geometric pattern, but non-hemodynamic factors, and specifically body composition, also influence 
prevalence of concentric LV geometry. Contrasting a general belief, it has been observed that adipose mass strongly 
influences LV mass, particularly in women, especially when fat-free mass is relatively deficient. Thus, though blood 
pressure control is mandatory for prevention and reduction of LVH in obese hypertensive patients, without reduction 
of visceral adiposity regression of LVH is difficult. Future researches should be addressed on (1) assessing whether 
LVH resulting from alteration of body composition carries the same prognosis as pressure overload LVH; (2) defining 
tissue characterization of the hypertrophic heart in obese-hypertensive patients; (3) evaluating whether assessment 
of hemodynamic loading conditions and biological markers can help defining management of the association of 
obesity with hypertension.
Keywords: Obesity, Hypertension, Left ventricular mass, Body composition
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In this mini-review we will examine the impact of obesity 
in the hypertensive population, focusing on the common 
cardiovascular changes and interaction, leading to con-
siderations on sex difference and body composition and 
potential influence on management (Fig. 1).
Obesity as a comorbidity in arterial hypertension
More than 80% of hypertensive patients present with 
additional risk factors, including glucose intolerance, 
hyperinsulinemia, lipid disorders (reduced HDL-choles-
terol and increased LDL-cholesterol and triglycerides) 
and obesity [1–4]. More than 50% of hypertensive 
patients present at least 2 of these comorbidities and, 
generally, one of those is obesity [4].
There is strong evidence that the prevalence of hyper-
tension increases sharply with increasing body weight 
[2]. Scattered longitudinal analyses also suggest that obe-
sity is an important risk factor also for incident hyperten-
sion, especially in women [5, 6].
Recently, the Southern Community Cohort Study, a 
large population-based survey, reported the probability 
of hypertension rising from 56% in overweight partici-
pants, to 2.5 fold in class I/II obesity, and up to 4.5 times 
in morbid obese participants [7]. This sharp progression 
of probability is also evident in kids and adolescents [8–
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In a Caribbean population based study [10], among 
2023 5-to-16 year-old public school students, the preva-
lence of hypertension was 13% in normal-weight individ-
uals, raising to 23% in overweight and as much as 53% in 
obese subjects.
An important methodological issue, when assessing 
blood pressure in the obese patient, is the cuff size. Blood 
pressure measurement must take into account upper-arm 
circumference and the cuff size in both office and home 
setting [12]. Use of small cuff size causes overestimation 
of blood pressure and often increases the incidence of 
white coat or masked hypertension [13].
Cardiovascular modifications of obesity
Evaluation of obesity-related cardiovascular changes 
poses method problems, especially when normaliza-
tion for body size is needed. The traditional use of body 
surface area (BSA) is inappropriate, because of geomet-
ric inconsistencies between BSA and LV mass, but also 
because body weight (and therefor fat mass) is included 
in the computation of BSA [14]. Thus using BSA pro-
duces a substantial underestimation of the prevalence of 
LV hypertrophy (LVH) in population with high preva-
lence of obesity [15]. Using of allometric signal of body 
height, obtained in a reference population [14] and 
recently confirmed in a different cohort study [16], nearly 
doubles the population risk attributable to LVH, espe-
cially when prevalence of obesity is high [17].
Observation of cardiovascular modifications of obesity 
during adolescence are particularly helpful to highlight 
the consistency of abnormalities of obesity with those 
found in the context of arterial hypertension.
In the young obese offspring participants of the Strong 
Heart Family Study cohort [18], although prevalence of 
occasional high BP was low (10% in the obese sub-popu-
lation), clear-cut LV hypertrophy (LVH) was progressively 
greater in overweight and obese adolescents compared to 
normal-weight individuals, paralleling the magnitude of 
adipose mass (Fig. 2). LV geometry was mainly eccentric 
[18]. In the HyperGEN registry [19], the impact of obesity, 
diabetes and dyslipidemia (labeled generically as ≪meta-
bolic risk factors≫) were assessed relatively to the prob-
ability of LVH in both normotensive and hypertensive 
subjects. The probability of LVH in normotensive partici-
pants with 1 or more metabolic risk factors was as high 
as the probability of LVH in hypertensive subjects with-
out any of them, and was independently related to central 
fat distribution and associated ≪metabolic risk factors≫. 
The association of metabolic risk factors with hyperten-
sion increases remarkably the probability of LVH.
The proportion of LV concentric geometry, the most 
deleterious LV geometric pattern [20], sharply raises dur-
ing middle age [21, 22] and becomes the most frequent 
LV geometric patterns among obese individuals [23, 24]. 
Thus, the association of obesity with hypertension pro-
duces a combined pressure and volume overload, which 
Fig. 1 Physiologic changes promoting common cardiovascular modifications in obesity and hypertension. OSA obstructive sleep apnea, LV left 
ventricular
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yields specific LV geometric abnormalities [20] and the 
most severe degrees of LVH, similar to that reported for 
the hemodynamic overload caused by specific valvular 
heart disease producing combined volume and pressure 
overload [19] [25].
The traditional paradigm of cardiovascular modifica-
tions in obesity with hypertension has been that obese 
individuals mostly develop eccentric LVH, due to the 
increased volume overload [26, 27]. However, this para-
digm, is changing [28], because of the increasing evidence 
that concentric LV geometry is very prevalent in obese 
individuals [21, 22, 24, 29]. In a population sample of 
hypertensive New York employees [23], the combination 
of hypertension and obesity was associated with a greater 
prevalence of concentric LVH than in normal-weight 
participants. Woodiwiss et  al. [29] studied a population 
sample of untreated hypertensive patients and found that 
obesity promotes LV concentric remodeling and hyper-
trophy rather than eccentric LVH. Similarly and more 
recently, Turkbey et  al. [24] found that concentric LVH 
was the most frequent LV geometric pattern in obesity, 
using magnetic resonance imaging in the large popula-
tion of the MESA study, forcing one to consider revising 
the prevalent viewpoint [28].
In obese patient, the increase in relative wall thickness 
(the most used index of concentricity) and LV mass is 
also typically associated with evidence of subclinical LV 
systolic dysfunction, especially when hypertension coex-
ists, such as depressed midwall shortening, abnormal 
reduced tissue myocardial velocities, strain and strain 
Fig. 2 Systolic blood pressure (BP, a), adipose mass (b), left ventricular (LV) diastolic diameter (c) and prevalence of LV hypertrophy (d) in normal 
weight (n = 114), overweight (n = 113) and obese adolescents (n = 223). Note that prevalence of LV hypertrophy follows the excess of adipose 
mass, more than BP or LV chamber dimension. Adapted from Ref. 12. Asterisk significant vs normal weight subgroup; dagger significant vs over-
weight subgroup
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rate [30, 31]. In the presence of concentric LV geom-
etry, ejection fraction is an imprecise marker of systolic 
function [32], because the cardiomyocyte contraction 
is amplified across the wall thickness by the interplay 
of cross-fiber thickening and shortening of differently 
aligned muscular fibers [33, 34].
Many mechanisms have been proposed to explain the 
association of obesity with hypertensive target organ 
damage, including enhanced sympathetic system activ-
ity, production of inflammatory cytokines and endothe-
lial dysfunction [35–37]. These mechanisms are related 
to the circulatory and tissue conditions associated with 
obesity.
Abnormal conditions associated 
with cardiovascular modifications in obesity
Hemodynamic load
Two conditions are frequent in obesity, potentially 
helping explaining the prevalent concentric LV geom-
etry: severe obstructive sleep apnea (OSA) and masked 
hypertension.
OSA has been demonstrated to elicit concentric LV 
geometry [38], substantially due to the frequent pressure 
overload due to the phases of apnea and the consequent 
drop of O2 saturation [39]. OSA also causes a chronic 
mild inflammatory status, a characteristic frequently 
reported in the context of central obesity [40].
Another stimulus to continuous pressure overload is 
masked hypertension, reported to be more frequent in 
obesity [41]. The reasons of this association is not com-
pletely clear. Cardiac output is greater in obesity, in rest-
ing conditions, and daily activities might further increase 
output to a level that is not compensated by adequate 
decrease in both pulsatile and steady components of arte-
rial impedance, to maintain normal blood pressure [42], 
mainly due to obesity associated endothelial dysfunction 
[43–45]. This abnormal adaptation generates a pressure 
overload superimposed to the “natural” volume overload 
pattern seen in obesity. Advanced glycation end-products 
and peri-vascular fat might contribute to the mismatch 
between flow output and vascular capacitance [46, 47].
In addition to the hemodynamic changes that help 
explaining prevalence of concentric LV geometry, there 
is also some evidence that increased sarcomere produc-
tion is not the sole phenomenon to be involved in the 
increased myocardial mass occurring in obesity [48].
Body composition
A paradigm in the pathophysiology of obesity is that the 
increased LV mass is a function of the increased fat-free 
mass, a typical feature of increased body weight also 
among obese individuals [49, 50], whereas adipose mass 
has little influence [51, 52]. However, body composition 
has an important impact on LV geometry in hyperten-
sive-obese individuals. When the visceral component of 
adipose mass is considered, a close correlation with LV 
mass becomes evident [53, 54], with differences between 
men and women.
On epidemiological scale, in women, the importance 
of adipose mass on variability of LV mass is as high as 
that of arterial hypertension [50], whereas fat-free mass 
is independently related to LV mass in both men and 
women. The “cardiac steatosis” also has functional con-
sequences in women but not in men [55]. The statistical 
effect of adipose mass on variability of LV mass in women 
is interrelated to the visceral distribution, as indicated by 
the significant impact of waist-to-hip ratio (Fig. 3).
Adipose mass also influences LV geometry. In a clinical 
study involving lean, obese and former-obese individuals 
[56], LV relative wall thickness, a potent measure of con-
centric LV geometry, was closely related to adipose mass 
(mostly intra-abdominal), and not to lean body mass. 
This relation was even closer than the relation of rela-
tive wall thickness with systolic BP. Based on these find-
ings, one might postulate that visceral fat contributes by 
non-hemodynamic pathways to the development of con-
centric LV geometry in obese individuals. If this postu-
late holds truth, one may speculate that in obese subjects 
with severe abnormalities of body composition (i.e. with 
excess body fat/fat-free mass deficiency), LVH and LV 
concentric geometry should be even more severe.
Adipose mass and LV geometry
We specifically studied the effect of fat mass in a special 
sub-population of obese individuals exhibiting a rela-
tive deficiency of fat-free mass and a consequent excess 
of adipose mass [54], a condition that is sometimes 
defined as ≪sarcopenic obesity≫  [57]. The identifica-
tion of this condition is not easy because in obesity fat-
free mass is always increased in absolute terms [49, 50, 
58]. In the strong heart study cohort, a relative fat-free 
mass deficiency was found in 46% of the obese popula-
tion, a characteristic that was substantially more frequent 
in women than in men. According to the old paradigm 
of LV mass only related to fat-free mass, lower LV mass 
could be expected in obese individuals with relative fat-
free mass deficiency. In contrast, though formed by the 
90% of women, this relatively ≪sarcopenic≫  sub-group 
exhibited larger LV chamber size and greater LV mass 
(even when normalizing for fat-free mass) with a clear 
trend toward concentric LV geometry. This peculiar LV 
geometric pattern was associated with values of blood 
pressure similar to the subgroup of obese subjects with 
normal fat-free mass, the same prevalence of diagnosed 
arterial hypertension, but higher inflammatory mark-
ers. It is clear that in this context, the increased LV mass 
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cannot be considered as a pure consequence of biological 
mechanisms induced by the hemodynamic load.
There is a further demonstration that hypertensive 
LVH developing in obesity is unmatched with hemo-
dynamic loading condition. When LV geometric adap-
tation is evaluated in relation to the need to sustain 
hemodynamic load, obesity is associated with excess of 
LV mass, in both men and women, relative to the mag-
nitude of myocardial mass that would be adequate to 
sustain the individual hemodynamic load [50]. Women, 
in whom sarcopenia is much more prevalent, exhibit 
levels of excess of LV mass substantially greater than 
men, strongly suggesting, therefore, that there might be 
alterations in the normal myocardial structure associ-
ated with the increased LV mass. The complex of these 
findings forces to reconsider the old Virkow’s definition 
of ≪the fatty heart≫ [59].
There is strong evidence that overnutrition produces 
adipocyte infiltration in the liver, pancreas, kidney, mus-
cles and heart, and triglycerides accumulate into the 
cells [60]. At the heart level, this has been directly dem-
onstrated using cine-magnetic resonance imaging and a 
technique called ≪localized proton spectroscopy≫ , able 
to identify exactly the triglyceride peak. The amount of 
triglycerides in the myocardium is closely related to BMI 
and has been directly demonstrated in specimens using 
oil red O staining [55, 56, 61]. Thus, the measure of LV 
mass in obese individuals includes cell populations and 
cell components that are different from what measured 
in lean subjects. The increased amount of fat infiltrating 
the myocardium carries 2 important functional conse-
quences, the overwhelming availability of fatty acids and 
the consequent increase in insulin resistance [62, 63]. 
The consequence of this biological alteration is a switch 
in the energy production, with the further reduction of 
carbohydrate oxidation and the overwhelming fatty acids 
oxidation which is a less efficient way to produce energy 
[64]. The reduced myocardial mechano-energetic effi-
ciency related to fatty acid oxidation carries negative 
effects in terms of cardiovascular outcome and is sub-
stantially more prevalent in obesity [65].
Thus, the increased LV mass in obesity is related not 
only to the increased muscle component, which is elic-
ited by the increased hemodynamic load. The expan-
sion of myocardial tissue related to non-muscular 
components (adipocyte infiltration, fibrosis, cardiomyo-
cyte thickening) [60, 61] helps understanding the ten-
dency to more prevalent concentric LV geometry, as the 
ratio between fat and fat-free mass increases. Under this 
scenario, the concentric LV geometry related to obesity 
would not be a consequence of cardiomyocyte thickening 
due to parallel superimposition of sarcomeres, but rather 
infiltration of non-muscular components [48]. Superim-
posing arterial hypertension to this unfavorable struc-
tural pattern produces the greatest levels of LVH because 
of both hemodynamic (combined pressure and volume 
overload) and non-hemodynamic reasons (fat infiltration, 
inflammation).
Fig. 3 Relative contribution of parameters associated with variance of LV mass index, by standardized β-coefficients obtained by multiple linear 
regression analysis in the cohort of the Strong Heart Study. Adipose mass together with waist-to-hip ratio exhibit significant association with LV 
mass index variance only in women. From Ref. [50]
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Blood pressure control in the obese patient
In general, the hemodynamic pattern typical of the com-
bination of obesity and hypertension is characterized by 
increased intravascular volume component that should 
be taken into account when managing arterial hyperten-
sion [20].
Controlling blood pressure is difficult in the presence 
of obesity. In the Campania Salute Network, the prob-
ability to optimally control blood pressure decreases with 
increasing BMI, despite the greater number of medica-
tions used [66, 67]. The frequency of increased BP despite 
aggressive therapy in the context of obesity is likely to be 
due to mechanisms related to the autocrine and parac-
rine activity of perivascular fat, namely the production 
of angiotensin II and aldosterone, making peculiar the 
origin of hypertension in obese individuals [68]. We also 
postulate that studying the characteristics of the hemo-
dynamic load might help understanding a more patho-
physiologic way to manage arterial hypertension in the 
presence of obesity, based on the combination between 
types of hemodynamic overload and metabolic abnor-
malities, as we have recently proposed [22].
Even in the presence of good control of BP, not neces-
sarily LV mass follows the decrease in BP when obesity is 
present. In the HyperGEN registry, partial correction of 
metabolic abnormalities and high BP characterizing met-
abolic syndrome, but without reduction of central obe-
sity, did not result in a corresponding lower LV mass [69], 
suggesting that a consistent reduction of LV mass cannot 
be achieved in this context without a program of weight 
reduction (Fig. 4).
Weight loss and regression of cardiovascular 
abnormalities
Dietary intervention and bariatric surgery are the main-
stay for obesity treatment. Abnormal LV geometry and 
function can substantially improve after weight loss in 
both adults and adolescents. Weight loss is associated 
with reduction of LV hypertrophy in obese individuals 
[70, 71], an effect that is even more evident, compared 
with the effect of blood pressure reduction on reduction 
of LV mass [49, 72]. In observational studies of high-risk 
hypertensive patients, a given decrease in blood pressure 
is less effective to reduce LV mass when obesity is present 
[73].
An extreme option is bariatric surgery, which is very 
effective to control the cluster of obesity-related car-
diovascular risk factors, hypertension and diabetes (or 
insulin-resistance) [74]. In adults with morbid obesity, 
weight loss after bariatric surgery is associated with 
improvement of LV systolic function and normalization 
of LV geometry also due to the consistent reduction of 
systolic BP [75, 76]. After bariatric surgery, even adoles-
cent obese subjects exhibit regression of LV hypertro-
phy and a trend toward normalization of LV concentric 
geometry [77].
Current recommendations and need for research
LVH is the most relevant marker of cardiovascular risk in 
arterial hypertension and current guidelines strongly rec-
ommend decrease LV mass. However, given the particu-
larity of LVH in the combination of arterial hypertension 
with obesity, whether or not LVH has the same prognos-
tic impact in both obese and non-obese hypertensive 
individuals is still unclear.
Current guidelines for arterial hypertension [78, 79] 
do not have specific suggestions for treatment of arterial 
hypertension and regression of LVH in the presence of 
obesity. Also, the recent recommendations for the man-
agement of obesity [80, 81], while strongly suggesting the 
study of body composition and highlighting the peculiar-
ities of the combination of obesity with hypertension, do 
not have clear indication on management.
We think that efforts should be oriented to characterize:
1. Whether LVH has the same pathophysiological 
meaning and, therefore, prognostic impact in both 
obese and non-obese men and women;
2. The tissue characterization of the hypertrophic heart 
in obese-hypertensive patients, a possibility emerging 
from new technologies applied to nuclear magnetic 
resonance [82, 83];
3. Whether extensive assessment of hemodynamic 
loading conditions and biological markers can help 
defining management of the association of obesity 
Fig. 4 Prevalence of single components of metabolic syndrome 
(MetS), according to the NCEP-ATPIII definition, in the participants in 
the HyprGEN study (from Ref. 47). Columns represents the prevalence 
in the sub-population without MetS (white) or with present MetS 
(grey) or with diagnosis of MetS, partially controlled by treatment 
of single components. Prevalence of all risk factors is significantly 
reduced in the managed MetS sub-group (0.05 < p < 0.0001), except 
central fat. LV hypertrophy is not influenced by the control of those 
risk factors, including hypertension
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with hypertension even beyond the crude interven-
tion on loading conditions.
Conclusions
Obesity and hypertension are closely linked conditions. 
Obesity exaggerates LV response to increased hemody-
namic load in large part throughout the effect of non-
hemodynamic mechanisms elicited by visceral adiposity. 
Fat mass is as important as, and perhaps more impor-
tant than, fat-free mass to promote increase in LV mass 
in visceral obesity, which is especially evident in women, 
related to their body composition. Body composition is 
likely to be a key factor in determining LV geometry in 
the presence of obesity and is at the basis of the para-
doxical sex-difference found in LV adaptation to arterial 
hypertension. Effectively controlling BP and reducing 
hypertensive LVH is difficult without managing obesity. 
Research should be implemented to find more adequate 
approach to manage this frequent combination.
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